XFOR, US98420X2027

X4 Pharmaceuticals stock fell 4.48 percent on October 6

Published on 10/07/2026 at 06:31 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

X4 Pharmaceuticals granted 80,000 options at USD 2.90 on October 1. The 4WARD trial targets 126 participants, while consensus centers at USD 11.50.

XFOR, US98420X2027, Illustration mit AI erstellt.

X4 Pharmaceuticals (ISIN US98420X2027) fell 4.48 percent to USD 2.77 on Nasdaq on October 6, 2026, placing the stock USD 0.07 above its 52-week low of USD 2.70. The move came as the biotechnology company prepared for its next clinical and financial milestones.

Options mark new employee awards

On October 1, 2026, GlobeNewswire reported that X4 granted inducement options covering 80,000 shares. The awards carry an exercise price of USD 2.90, equal to the September 30, 2026 closing price, and vest over four years.

The option price stood USD 0.13 above the October 6 stock price, a gap of 4.7 percent. That relationship gives the grant a concrete market reference while keeping the company focused on hiring and execution.

4WARD trial targets 126 patients

X4's more important operating checkpoint is mavorixafor, marketed as XOLREMDI, and its Phase 3 4WARD trial in chronic neutropenia. In a September 8, 2026 release, GlobeNewswire said the FDA accepted a reduction in planned enrollment from 176 to 126 participants while retaining the trial's co-primary endpoints.

The same release set completion of enrollment by the end of 2026 and topline data for the first half of 2028. The trial is designed to measure annualized infection rates and absolute neutrophil count response, making execution speed a central valuation variable.

Consensus remains above the stock

For the second quarter of 2026, X4 reported revenue of USD 8.81 million and an adjusted loss of USD 0.13 per share against a consensus loss of USD 0.18, according to MarketBeat in its October 5, 2026 report. The earnings comparison was favorable, but the company remained loss-making during the quarter.

Analyst sentiment is more optimistic than the chart. Paasa lists 12 buy ratings, 1 hold and 0 sell ratings, with a median consensus target of USD 11.50. That target lies 315.2 percent above the October 6 price, a wide spread that places substantial weight on the 4WARD development path.

Stock trades near yearly low

X4 Pharmaceuticals closed at USD 2.77 on Nasdaq on October 6, 2026, after trading between USD 2.70 and USD 2.90. Volume reached 642,467 shares and market capitalization stood at USD 261.3 million as of the same date.